Stargardt Disease (STGD) and Macular Dystrophies Panel
Summary and Pricing ![](img/next-arrow.png)
Test Method
Exome Sequencing with CNV DetectionTest Code | Test Copy Genes | Panel CPT Code | Gene CPT Codes Copy CPT Code | Base Price | |
---|---|---|---|---|---|
4315 | Genes x (28)![]() | 81479 | 81404(x1), 81406(x2), 81408(x1), 81479(x52) | $990 | Order Options and Pricing |
Pricing Comments
We are happy to accommodate requests for testing single genes in this panel or a subset of these genes. The price will remain the list price. If desired, free reflex testing to remaining genes on panel is available. Alternatively, a single gene or subset of genes can also be ordered via our Custom Panel tool.
An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.
Click here for costs to reflex to whole PGxome (if original test is on PGxome Sequencing platform).
Click here for costs to reflex to whole PGnome (if original test is on PGnome Sequencing platform).
Turnaround Time
3 weeks on average for standard orders or 2 weeks on average for STAT orders.
Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.
Targeted Testing
For ordering sequencing of targeted known variants, go to our Targeted Variants page.
Clinical Features
Stargardt disease (STGD) is a juvenile onset form of macular dystrophy/degeneration (MD) characterized by loss of photoreceptor cells in the macula, resulting in a severe reduction of central vision with a variable phenotype and a variable age of onset and severity. STGD is considered one of the most frequent causes of MD in childhood, accounting for approximately 7% of all retinal degenerative diseases with an estimated prevalence of 1 in 10,000 and a carrier frequency of 2% (Shastry. 2008. PubMed ID: 18506364). Clinical features include progressive bilateral degeneration of the macula and retinal pigment epithelium (RPE) with characteristic orange-yellow flecks located around the macula or the mid peripheral retina (Rossi et al. 2012. PubMed ID: 23341817). The hallmark of STGD is massive accumulation of cellular debris, presumably lipofuscin in the RPE (usually seen in normal aging human eyes) (Fishman et al. 1987. PubMed ID: 3658351), which is clinically similar to fundus flavimaculatus (FFM) that has a later age of onset (20-64 years) and slower progression or milder visual loss compared to STGD (Kaplan et al. 1993. PubMed ID: 8275096).
Genetics
Genetically, STGD is a heterogeneous disorder that is usually inherited in an autosomal recessive (AR) manner and, less commonly, as an autosomal dominant (AD) trait (Rossi et al. 2012. PubMed ID: 23341817). Using homozygosity mapping, the STGD1/FFM disease locus was mapped to the short arm of chromosome 1, and the causative gene characterized as ABCA4 (Kaplan et al. 1993. PubMed ID: 8275096; Allikmets et al. 1997. PubMed ID: 9054934). Panel-based next generation sequencing has identified other genes (BEST1, C1QTNF5, CDH3, CNGB3, ELOVL4, FSCN2, PROM1, PRPH2, RDH12, RP1L1, RPGR, TIMP3, RBP3, RPGRIP1, EFEMP1, GUCA1B, CERKL, CRB1, RLBP1, RS1, IMPG2, CTNNA1, HMCN1, CFH, IMPG1, MFSD8, and PRDM13) reported to cause STGD like phenotype or macular dystrophies similar to STGD (Zhang et al. 2014. PubMed ID: 24763286; Strom et al. 2012. PubMed ID: 22863181; Petrukhin et al. 1998. PubMed ID: 9662395; Glöckle et al. 2014. PubMed ID: 23591405; Zaneveld et al. 2015. PubMed ID: 25474345; Saksens et al. 2016. PubMed ID: 26691986; Small et al. 2016. PubMed ID: 26507665).
Please note that this test also targets the five variants in the upstream region of the PRDM13 gene that were reported to segregate with disease in the 102 affected and 39 unaffected members of the 12 North Carolina macular dystrophy (NCMD) families (Small et al. 2016. PubMed ID: 26507665).
See individual gene test descriptions for information on molecular biology of gene products and spectra of pathogenic variants.
Clinical Sensitivity - Sequencing with CNV PGxome
Due to genetic heterogeneity and phenotypic overlap, determining clinical sensitivity is difficult. A study that screened 23 families with both Stargardt disease (STGD) and Age-related Macular Degeneration (AMD), detected causative ABCA4 pathogenic variants in 37/46 chromosomes (80%), which is substantially higher than the previous reports (~63%) (Shroyer et al. 2001. PubMed ID: 11726554; Yatsenko et al. 2003. PubMed ID: 12754711).
Large deletions/duplications have been reported in ABCA4, BEST1, CDH3,CNGB3, PROM1, PRPH2, RDH12, RPGR, RPGRIP1, CRB1, RLBP1, RS1, CFH, and IMPG2 (Human Gene Mutation Database).
Testing Strategy
This test is performed using Next-Gen sequencing with additional Sanger sequencing as necessary.
This panel typically provides 98.8% coverage of all coding exons of the genes plus 10 bases of flanking noncoding DNA in all available transcripts along with other non-coding regions in which pathogenic variants have been identified at PreventionGenetics or reported elsewhere. We define coverage as ≥20X NGS reads or Sanger sequencing. PGnome panels typically provide slightly increased coverage over the PGxome equivalent. PGnome sequencing panels have the added benefit of additional analysis and reporting of deep intronic regions (where applicable).
RP1L1 does not have 100% coverage for a few regions in exon 4.
This test also targets the five variants in the upstream region of the PRDM13 gene (see the Genetics section).
We also test a deep intronic variant (c.2077-521A>G) in PROM1 (Mayer et al. 2016. PubMed ID: 26153215).
We do not test for all the deep intronic variants in ABCA4. However, if we find a pathogenic or a likely pathogenic in ABCA4 or another of these genes in this panel, we will perform Sanger backfill of the remainder of the gene.
The following list of deep intronic variants in ABCA4 are tested when a single likely pathogenic or pathogenic variant is identified: c.161-23T>A, c.570+1798A>G, c.769-784C>T, c.859-506G>C, c.859-540C>G, c.1937+435C>G, c.1938-619A>G, c.2160+584A>G, c.2919-826T>A, c.3050+370C>T, c.4253+43G>A, c.4539+1100A>G, c.4539+2001G>A, c.4539+2028C>T, c.4539+2064C>T, c.5196+1056A>G, c.5196+1136C>A, c.5196+1137G>T, c.5196+1159G>A, c.5196+1216C>A, c. 6006-609T>A, c.6148-471C>T.
We do not have coverage for the RPGR ORF15 region in this panel.
Dependent on the sequencing backbone selected for this testing, discounted reflex testing to any other similar backbone-based test is available (i.e., PGxome panel to whole PGxome; PGnome panel to whole PGnome).
Indications for Test
All patients with symptoms suggestive of Stargardt and macular dystrophies are candidates.
All patients with symptoms suggestive of Stargardt and macular dystrophies are candidates.
Genes
Official Gene Symbol | OMIM ID |
---|---|
ABCA4 | 601691 |
BEST1 | 607854 |
C1QTNF5 | 608752 |
CDH3 | 114021 |
CERKL | 608381 |
CFH | 134370 |
CNGB3 | 605080 |
CRB1 | 604210 |
CTNNA1 | 116805 |
EFEMP1 | 601548 |
ELOVL4 | 605512 |
FSCN2 | 607643 |
GUCA1B | 602275 |
HMCN1 | 608548 |
IMPG1 | 602870 |
IMPG2 | 607056 |
MFSD8 | 611124 |
PRDM13 | 616741 |
PROM1 | 604365 |
PRPH2 | 179605 |
RBP3 | 180290 |
RDH12 | 608830 |
RLBP1 | 180090 |
RP1L1 | 608581 |
RPGR | 312610 |
RPGRIP1 | 605446 |
RS1 | 300839 |
TIMP3 | 188826 |
Inheritance | Abbreviation |
---|---|
Autosomal Dominant | AD |
Autosomal Recessive | AR |
X-Linked | XL |
Mitochondrial | MT |
Diseases
Related Test
Name |
---|
PGxome® |
Citations ![](img/next-arrow.png)
- Allikmets et al. 1997. PubMed ID: 9054934
- Fishman et al. 1987. PubMed ID: 3658351
- Glöckle et al. 2014. PubMed ID: 23591405
- Human Gene Mutation Database (Bio-base).
- Kaplan et al. 1993. PubMed ID: 8275096
- Mayer et al. 2016. PubMed ID: 26153215
- Petrukhin et al. 1998. PubMed ID: 9662395
- Rossi et al. 2012. PubMed ID: 23341817
- Saksens et al. 2016. PubMed ID: 26691986
- Shastry. 2008. PubMed ID: 18506364
- Shroyer et al. 2001. PubMed ID: 11726554
- Small et al. 2016. PubMed ID: 26507665
- Strom et al. 2012. PubMed ID: 22863181
- Yatsenko et al. 2003. PubMed ID: 12754711
- Zaneveld et al. 2015. PubMed ID: 25474345
- Zhang et al. 2014. PubMed ID: 24763286
Ordering/Specimens ![](img/next-arrow.png)
Ordering Options
We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.
myPrevent - Online Ordering
- The test can be added to your online orders in the Summary and Pricing section.
- Once the test has been added log in to myPrevent to fill out an online requisition form.
- PGnome sequencing panels can be ordered via the myPrevent portal only at this time.
Requisition Form
- A completed requisition form must accompany all specimens.
- Billing information along with specimen and shipping instructions are within the requisition form.
- All testing must be ordered by a qualified healthcare provider.
For Requisition Forms, visit our Forms page
If ordering a Duo or Trio test, the proband and all comparator samples are required to initiate testing. If we do not receive all required samples for the test ordered within 21 days, we will convert the order to the most effective testing strategy with the samples available. Prior authorization and/or billing in place may be impacted by a change in test code.
Specimen Types
Specimen Requirements and Shipping Details
PGxome (Exome) Sequencing Panel
PGnome (Genome) Sequencing Panel
ORDER OPTIONS
View Ordering Instructions1) Select Test Type
2) Select Additional Test Options
No Additional Test Options are available for this test.